Biologically Active Substance – Talk Bio

Actionable Insights Powered by AI

Novo Nordisk Foundation Commits Over $850M to Danish Life Science Incubator BII Over Next Decade

16 hours ago talkbio0Tagged BII, biotech startups, Denmark, life science incubator, methionine, Novo Nordisk Foundation

Novo Nordisk Foundation; BII; life science incubator; $850M; biotech startups; Denmark

Novo Nordisk Refocuses on Diabetes and Obesity to Expand GLP-1 Market at JPM26

2 days ago talkbio0Tagged Diabetes, Glucagon-Like Peptide 1, JPM26, Mike Doustdar, Novo Nordisk, Obesity, semaglutide, Wegovy pill

Novo Nordisk; diabetes; obesity; GLP-1; JPM26; Mike Doustdar; Wegovy pill; semaglutide

JPM26: Novo Nordisk and Eli Lilly Compete Fiercely in Oral Obesity Treatments

2 days ago talkbio0Tagged eli lilly, JPM26, JPMHC, Novo Nordisk, oral obesity drugs, orglipron, semaglutide

Novo Nordisk; Eli Lilly; oral obesity drugs; JPM26; JPMHC; orglipron; semaglutide

BioNTech and UPenn Launch $50M Seed Fund for Early-Stage Biotechs

4 days ago talkbio0Tagged BioNTech, biotech startups, methionine, RNA, Messenger, seed fund, UPenn

BioNTech; UPenn; seed fund; $50M; mRNA; biotech startups

Enliven’s Phase 1b ELVN‑001 leukemia pill shows competitive efficacy vs. Novartis and Terns CML TKIs

7 days ago talkbio0Tagged asciminib, BCR-ABL1, Contraceptives, Oral, Deep molecular response, ELVN-001, ENABLE trial, Enliven Therapeutics, Inhibitor, Measles-Mumps-Rubella Vaccine, Molecular Response, Myeloid Leukemia, Chronic, Novartis, Phase 1b, Protein-tyrosine kinase inhibitor, T315I, TERN-701, Terns, TKI, WDR20 gene

Enliven Therapeutics; ELVN-001; Phase 1b; chronic myeloid leukemia; CML; BCR-ABL1 inhibitor; major molecular response; MMR; deep molecular response; DMR; asciminib; Novartis; Terns Pharmaceuticals; TERN-701; T315I; ENABLE trial; CML pill; tyrosine kinase inhibitor; TKI; best-in-class

MoonLake revives FDA push; biotech trio to debut in Hong Kong

7 days ago talkbio0Tagged * * Investor Day, Asia, Biological Factors, Blackfoot language, Capital, Hidradenitis Suppurativa, Hong Kong, HS drug approval pathway, immunotherapeutics, License Application, Market, MIRA trial, MoonLake, sonelokimab, Type B meeting, United States Food and Drug Administration, VELA-1 trial, VELA-2 trial

MoonLake Immunotherapeutics; Sonelokimab; Hidradenitis Suppurativa; FDA Type B meeting; Biologics License Application; BLA H2 2026; VELA-1 trial; VELA-2 trial; MIRA trial; HS drug approval pathway; investor day February 23 2026; Hong Kong biotech IPOs; Hong Kong listing; Asia biotech capital markets

AstraZeneca appoints Rick R. Suarez to lead U.S. BioPharmaceuticals business and $50B investment drive

7 days ago talkbio0Tagged AstraZeneca, Biological Factors, Head of US, Investments, President brand of dental material, Rick R. Suarez, Surgical aspects, U.S., Virginia manufacturing facility, Wilmington Delaware

AstraZeneca; Rick R. Suarez; US President; Head of US BioPharmaceuticals Business Unit; $50 billion US investment; Virginia manufacturing facility; US operations; biopharmaceuticals; revenue goal 2030; Wilmington Delaware

Rakuten Medical Raises $100 Million in Oversubscribed Series F for Photoimmunotherapy Platform

1 week ago talkbio0Tagged Alluminox, Cancer Therapeutic Procedure, methionine, Photoimmunotherapy, Rakuten Medical, regulatory approval, Series F

Rakuten Medical; Series F; $100M; photoimmunotherapy; cancer therapy; Alluminox; regulatory approval

Syncromune Appoints Dr. Stephen P. Dale as Chief Medical Officer

1 week ago talkbio0Tagged Appointments, Biological Factors, Chronic multifocal osteomyelitis, Neoplasms, Stephen P. Dale, SYNC-T, Syncromune

Syncromune; Stephen P. Dale; CMO; appointment; oncology; SYNC-T; biopharmaceutical

Crinetics Reports Over $5M in Q4 2025 PALSONIFY Revenue with Strong Launch Metrics

1 week ago talkbio0Tagged Acromegaly, Crinetics, enrollment forms, methionine, PALSONIFY, prescribers, Q4 2025, Revenue

Crinetics; PALSONIFY; Palsonify; Q4 2025; revenue; $5M; acromegaly; enrollment forms; prescribers